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III. Abstract 
Therapeutic hypothermia is a standardized protocol in the management of term- or near-
term neonates who have suffered asphyxia in the perinatal period. Birth asphyxia, if sustained, 
may develop into a more serious condition known as hypoxic ischemic encephalopathy (HIE). 
Depending on severity, HIE is associated with adverse cognitive and neurodevelopmental 
outcomes, yet through various physiological mechanisms, hypothermia sustained for a 72-hour 
period has been shown to attenuate, or even prevent, permanent brain damage by decreasing 
cerebral energy demands. Unfortunately, cognitive and neurodevelopmental outcomes are 
difficult to prognosticate before or after completion of hypothermia protocol, but existing 
standards and technology allow for reliable prognostication up at 18 months of age. Currently, 
research is underway to identify certain imaging and biochemical modalities that may help 
predict cognitive and neurodevelopmental outcomes at various stages of childhood beyond 18 
months of age, even before hypothermia is initiated, as well as to evaluate methods holding 
potential to strengthen hypothermia protocol as it presently stands.   
IV. Introduction 
Perinatal asphyxia is not an infrequent incidence, occurring between 1 to 2 per 1000 live 
births in the United States.1,2 When asphyxia is sustained, hypoxic ischemic encephalopathy 
(HIE) may result. While the main sequelae of moderate to severe HIE are neuromotor delays, 
such as cerebral palsy (CP), which accounts for 20% of cases of neonatal HIE, cognitive 
impairments can also occur.3 When compared to neonates who do not experience hypoxic insults 
in the perinatal period, neonates with at least a moderate degree of HIE have a 10% increased 
risk of death, and those that survive carry a 30% increased risk of neurodevelopmental 
disabilities.4 
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Hypoxic insults that progress to HIE in the perinatal period are caused by cerebral 
ischemia. This lack of blood flow to the brain leads to deficiencies in oxygen, adenosine 
triphosphate (ATP), and glucose, creating an environment reliant on the anaerobic metabolism of 
lactate to meet energy needs, which in excess, leads to acidosis. Additionally, HIE triggers a 
release of excitatory glutamate that may cause neuronal hyperexcitability, seizure activity, and/or 
neuronal cell injury and death. Excess glutamate also increases production of reactive oxygen 
species (ROS) and nitric oxide (NO). ROS recruit inflammatory cytokines and enzymes that 
degrade the blood-brain barrier, leading to cerebral edema and a resultant increase in intracranial 
pressure (ICP), as well as increase apoptosis of neuronal cells. NO promotes cerebral capillary 
leakiness, which also increases ICP.1,2,5 
Mechanistically, therapeutic hypothermia, or cooling core body temperature below 37.5 
degrees Celsius (°C), decreases cerebral demand for oxygen, ATP, and glucose, to ultimately 
decrease lactate production and thwart acidosis. This cooling process also decreases release of 
glutamate from the brain, thereby attenuating ROS and NO production, which preserves the 
integrity of the blood-brain barrier, maintains normal ICP, and decreases inflammation and 
neuronal apoptosis. Therapeutic hypothermia experienced resurgence in the medical community 
in the 1950s, for notably decreasing cerebral blood flow, oxygen consumption, and ICP in 
patients undergoing cardiac surgery. Clinical application of and research into therapeutic 
hypothermia waned until the 1980s, until experimentation with milder hypothermic temperatures 
(i.e., greater than 32°C) began, including pilot research into applications for neonatal HIE in the 
late 1990s. In 2010, therapeutic hypothermia become a standard of practice for neonates of at 
least 36 weeks gestational age who had sustained asphyxia within 6 hours of birth, to minimize 
neurodevelopmental sequelae associated with HIE.1-8  
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The objective of the current research is to evaluate the efficacy of therapeutic 
hypothermia in improving neurodevelopmental outcomes in neonates with HIE, specifically by: 
1) exploring protocol-defining research into therapeutic hypothermia for neonatal HIE; 2) 
assessing subsequent neurodevelopmental outcomes at various stages in childhood; 3) examining 
the utility of certain imaging tests and biochemical measures at predicting neurodevelopmental 
outcomes before therapeutic HIE is initiated; and 4) reviewing potential mechanisms for 
strengthening current hypothermia protocol for neonatal HIE. 
V. Background: Literature Review 
Standardizing Cooling Protocol for Neonatal HIE 
 Before therapeutic hypothermia became standardized protocol for term or near-term 
neonates who had suffered perinatal asphyxia, intensive care unit level management was still 
indicated, along with maintenance of physiological parameters within normal range and 
treatment of seizure activity with anti-epileptic drugs. There were some experimental 
pharmaceutical treatments being used, such as phenobarbital for potential reduction of 
neurodevelopmental handicap at 3 years of age, or allopurinol, which was thought to improve 
electroencephalogram (EEG) activity and reduce formation of ROS. Nevertheless, there was a 
paucity of data exploring the long-term effects of said interventions, so there did not exist any 
standardized protocol before the advent of therapeutic hypothermia.1,2 
 After the resurgence of interest and research into utilization of therapeutic hypothermia in 
reducing cerebral metabolism in the late 1990s,5 small-scale randomized controlled trials (RCTs) 
examining the effects of mild hypothermia (i.e., core temperature of 33.5-34.5°C) on 
neurodevelopmental outcomes in neonates who had suffered perinatal asphyxia were conducted, 
but participant sizes were insufficient to yield adequate power to determine effectiveness in 
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clinical application.6-8 However, these initial studies did pioneer the methods for inducing 
hypothermia that would come to be used in protocol-defining RCTs: whole body and/or selective 
head cooling. The former provides homogenous cooling to peripheral and central brain 
structures, namely, the posterior limb of the internal capsule, white matter cortex, basal ganglia, 
and thalamus. The latter provides a greater degree of cooling to the periphery of the brain than to 
the central brain structures, so, it was found that whole body cooling, combined with a degree of 
head cooling, minimizes temperature gradient differences across the brain and facilitates more 
effective cooling to the deeper brain structures.1-4 
 Soon after the launch of these pilot studies, larger scale, multi-center RCTs of neonates 
with moderate to severe HIE assigned to hypothermia protocol, with matched controls receiving 
intensive care unit level management and euthermia, emerged.1, 2,4,9 The Eunice Kennedy Shriver 
National Institute of Child Health and Human Development Research Network (NICHD NRN) 4 
utilized whole-body cooling, and the CoolCap study employed selective head-cooling.9 The Total 
Body Hypothermia for Neonatal Encephalopathy (TOBY)1,2 began in 2002, and additionally 
summarized data from other RCTs, including NICHD NRN and CoolCap, to maximize 
participant size and study power, so the most effective assessment of therapeutic hypothermia in 
the setting of neonatal HIE and neurodevelopmental outcomes could be conducted.  
Per TOBY, neonates that met criteria for therapeutic hypothermia were at least 36 weeks 
gestational age and admitted to the neonatal intensive care unit, with at least one of the 
following: a) Apgar score of less than or equal to 5 at 10 minutes after birth; b) continued need 
for mechanical ventilation at 10 minutes after birth; c) acidosis within 60 minutes of birth; and/or 
d) base deficit greater than or equal to 16 mmol/L in any blood sample within 60 minutes of 
birth. Next, moderate or severe encephalopathy was defined as an altered state of consciousness, 
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characterized by lethargy, stupor, or coma, and at least one of the following (Table 1): a) 
hypotonia; b) abnormal reflexes, including oculomotor and pupillary; c) absent or weak suck; 
and/or d) clinical seizures. Within 6 hours of birth, whole-body cooling was initiated, with a 
rectal or esophageal probe monitoring temperature at 33.5°C for a duration of 72 hours. After 72 
hours, body temperature was raised gradually, at a rate of 0.5°C per hour, until 36.5°C was 
reached.1,2,4,9 
Immediately following the re-warming phase, magnetic resonance imaging (MRI) scans 
of the brain were conducted, along with assessments of both cognitive outcome per the Bayley 
Scales of Infant Development II (BSID II) and neurodevelopmental disability per the Gross 
Motor Function Classification System (GMFCS). Additionally, evaluations to assess hearing and 
vision impairment, as well as the existence of CP and/or seizure disorders, were performed. An 
identical battery of examinations was also performed when study participants reached 18 months 
of age.1,2,4,9 
Neurodevelopmental Outcomes at 18 Months of Age 
The general results ascertained from TOBY and the aforementioned RCTs were that 
across both cooled and non-cooled groups, the combined rates of mortality and severe 
neurodevelopmental disability were similar, in both the neonatal period and 18 months after 
birth. However, when looking at the survivors in each group, those who had received cooling 
were significantly more likely to be neurologically normal at 18 months of age, when compared 
to euthermic matched controls. Additionally, hypothermia was found to significantly reduce the 
risk of CP when compared to neonates who had received euthermic cares. Additionally, in these 
protocol-defining RCTs, there were no significant differences found in mortality or adverse 
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outcomes between cooled and non-cooled neonates, pointing to the safety of therapeutic 
hypothermia in neonates with HIE.1,2,4,9 
Neurodevelopmental Outcomes Beyond 18 Months of Age 
Despite these RCTs officially defining therapeutic hypothermia as protocol for 
management of neonatal HIE, the size of these trials were not large enough to allow for 
assessment of neurodevelopmental outcomes beyond 18 months of age.1,2,4,9 The minimum 
duration of follow-up required for accurately diagnosing neuromotor, neurosensory, and 
cognitive disability is 18 months of age, and long-term follow-up to at least 6 years of age is 
desirable for a detailed assessment of neurodevelopmental and cognitive functioning.1,2  
Even so, to date, the most prospective examination of neurodevelopmental outcomes at 
later points in childhood comes from secondary analysis of data from the NICHD NRN RCT and 
its associated 6-7 year follow-up outcomes study. Natarajan et al. 2013 evaluated the potential 
positive impact of therapeutic hypothermia in neonates with low 10-minute Apgar scores (i.e., 0-
3) on neurodevelopmental outcomes at 6 to 7 years of age. From the primary results of the 
NICHD NRN RCT, there was a 45% increase in the odds of death or disability at 18 months of 
age with each 1-point decrease in Apgar score at 10 minutes. This secondary analysis showed 
that of the survivors with 10-minute Apgar scores of 0 (n=11 out of 24), 5 survived without 
moderate to severe disability, and had either a normal or mildly impaired intelligence quotient, 
normal visuospatial development, normal executive functioning, and no CP at 6 to 7 years of 
age; of these 5 survivors, 3 had undergone cooling.10  
Early Predictors of Neurodevelopmental Outcome Before Hypothermia Initiation 
 Even with cooling therapy, over 40% of neonates with moderate to severe HIE die or 
suffer moderate to severe disabilities, such as CP, intellectual impairment, and epilepsy.11 As 
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such, clinicians are interested in early predictors of neurodevelopmental outcome before the 
initiation of therapeutic hypothermia, in order to provide the most accurate prognosis.12 The most 
accessible methods with prognosticating potential are imaging techniques and biochemical 
markers.  
MRI is currently accepted as the best method in the detection of perinatally-acquired 
brain lesions, and has been found to be predictive of abnormal neurodevelopmental outcome at 
18 months of age, especially if performed within 8 days of birth.1-3 However, in a more recent 
retrospective observational study, mild degrees of brain injury per MRI assessment in the 
perinatal period did not consistently equate to normal cognitive and language measures around 
24 months of age.13 Even so, MRI is still recognized as the optimal modality for imaging 
structural changes following cerebral insults in the perinatal period, as well as for 
prognosticating neurodevelopmental outcomes at later stages in childhood; yet, standardized 
cognitive and neurodevelopmental testing, as well as MRI imaging, should be done serially 
throughout childhood, to provide the most accurate assessments and prognoses.12 Amplitude of 
the filtered electroenceophalogram (aEEG) records trends in brain activity over a period of at 
least 24 hours. This is useful in monitoring neonates, because they have underdeveloped brains 
with activity signals that are not reliably recorded on EEG, and at most, provide only a snapshot 
of brain activity over a 45 to 60 minute period. aEEG is being increasingly used to assess and 
prognosticate the severity of neonatal encephalopathy following hypothermia protocol.12 Finally, 
cranial ultrasound is a portable, fast, and easily available imaging technique to assess brain 
abnormalities, and attractive in that it confers no radiation exposure to the neonate. While a 
normal cranial ultrasound is reassuring, an abnormal result is associated with a high false-
positive rate when predicting neurodevelopmental outcomes.12 
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Aside from the early prognostic potential of imaging procedures, certain biochemical 
markers may also be helpful in predicting neurodevelopmental outcomes before the onset of 
therapeutic hypothermia in neonates with HIE. A good biomarker is one that can be detected 
easily, rapidly, soon after birth, and also elevates in proportion to the degree of insult.12 Initial 
neonatal arterial pH, time to spontaneous respirations, and absence of intrapartum exposure to 
oxytocin have been associated with 70% of neonates admitted for therapeutic hypothermia, and 
who subsequently suffered severe brain injury, per abnormal brain MRI at 7-10 days after birth.14 
All of these variables, when measured soon after birth, have a high specificity and a high 
negative predictive value for prognosticating neurodevelopmental outcomes at 18 months of 
age.12 Glial fibrillary acidic protein (GFAP), a protein found in astrocytes; and ubiquitin 
carboxyl-terminal hydrolase L1 (UCH-L1), an enzyme found in dendrites, hold potential for 
reflecting the extent of neuronal injury, because they are released into circulation after 
breakdown of the blood-brain barrier following an ischemic injury. In a prospective cohort pilot 
study using data from NICHD NRN RCT, those with moderate to severe HIE had significantly 
greater concentrations of GFAP and UCH-L1 when compared to infants with mild HIE, yet 
GFAP was the only biomarker that correlated significantly with other indicators of multiple 
organ dysfunction, like low 5-minute Apgar scores, and at 6-24 hours of age, only GFAP was 
significantly more elevated in neonates with abnormal neurodevelopmental outcomes at 20 
months of age.12,15 Finally, creatine kinase brain band (CK-BB), an enzyme found in neurons and 
astrocytes; neuron-specific enolase (NSE), an enzyme found in neurons; and S100b, a protein in 
astrocytes and Schwann cells, are all biomarker specific for neuronal tissue, but they have not 
been shown to be consistently elevated in neonatal HIE or correlated with neurodevelopmental 
outcomes.12 Currently, no biochemical marker has been identified that meets all necessary 
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parameters for early prognostication of neurodevelopmental outcomes before hypothermia 
initiation in neonates with HIE, so prognosis continues to depend on serial cognitive and 
neurodevelopmental evaluation, along with neurophysiological tests and cerebral imaging into 
childhood.12 
Strengthening Current Hypothermia Protocol for Neonatal HIE 
 Regardless of therapeutic hypothermia being a standard of care for the management of 
neonatal HIE,5 new neuroprotective therapies will be necessary to reduce the unacceptably high 
risk of adverse outcomes after HIE.11 Although there were no significant differences found in 
adverse outcomes between cooled and non-cooled neonates in protocol-defining RCTs, 
hypotension, thrombocytopenia, prolonged coagulation times, and intracranial hemorrhage were 
still observed in both groups.1,2,4,9 Therapeutic hypothermia does hold potential for adverse 
outcomes, independent of HIE, which can be described in a systems-based format. In terms of 
the cardiovascular system, there exists a risk for arrhythmias, but mainly at temperatures below 
30°C. Additionally, the induction of peripheral vasoconstriction in the setting of hypothermia 
decreases venous return to the heart, which causes an increase in atrial natriuretic peptide and a 
decrease in antidiuretic hormone, leading to increased diuresis. In the pulmonary system, there is 
an increased risk for pneumonia, because hypothermia decreases the inflammatory response, and 
makes the neonate more susceptible to infection. Hematological changes include a dwindling 
platelet count at temperatures less than 35°C, and the impairment of the coagulation cascade at 
temperatures less than 33°C. From a gastrointestinal standpoint, hypothermia promotes ileus and 
delayed gastric emptying, which increases risk for small bowel obstruction, feeding intolerance, 
and difficulties with blood glucose management. As far as electrolyte and hormonal balance, 
hypothermia decrease serum potassium and insulin sensitivity. Pharmacokinetics are also 
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affected, in that hypothermia reduces the rates of tubular reabsorption and secretion of certain 
drugs, as well as inhibits the cytochrome P450 system.5 
 With these caveats to therapeutic hypothermia in mind, several studies have been 
conducted to better elucidate stronger safety parameters for, and potentially efficacy of, protocol 
as it currently stands in the management of neonatal HIE.11, 16, 17 A small, open-level phase I 
clinical trial was conducted to evaluate the safety and pharmacokinetics of high-dose 
erythropoietin (EPO) given to neonates with HIE undergoing hypothermia, because high doses 
(i.e., 250-2500 U/kg) of EPO have been shown to be neuroprotective in animal models of 
neonatal HIE, specifically lowering rates of death and moderate to severe CP, when compared 
with hypothermia treatment alone.11 In the open level, phase 1 clinical trial, 1000 U/kg EPO plus 
hypothermia only showed no worsening of neurodevelopmental outcomes when compared with 
hypothermia alone, per MRI assessment in the neonatal period.11 A secondary analysis of data 
from NICHD NRN RCT sought to highlight an advantage associated with birth location and 
induction of hypothermia; neonates born outside of centers performing hypothermia were 
considered “outborn,” while those born within centers performing hypothermia were considered 
“inborn.” After analysis, birth location had no significant impact on neurodevelopmental 
outcomes after therapeutic hypothermia.16 Finally, an observational study in neonates with 
congenital brain anomalies or syndromic diagnoses and HIE independent of said factors, 
evaluated any positive effects of hypothermia on neurodevelopmental outcome in a population 
that would not have otherwise met induction criteria. Three of the subjects (n=8) deceased in the 
neonatal period, and 3 out of 5 survivors had unfavorable neurodevelopmental outcomes, 
independent of HIE, when seen for follow-up at 26 months of age. Because congenital anomalies 
and syndromic diagnoses confer a possibility for adverse developmental outcomes independent 
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of HIE, risk versus benefit of therapeutic hypothermia induction in this population of neonates 
remains to be defined, necessitating larger RCTs with increased sample sizes.17 
VII. Methods 
 The framework for the present research was assembled using a PubMed Keyword search: 
“does therapeutic cooling in neonates with hypoxic brain injury improve outcomes?” Literature 
review was filtered to include only clinical trials and reviews, from the years 2000 to 2017.  
VIII. Discussion 
 
IX. Conclusion 
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